Abstract Understanding the prevalence of cancer-related visits by physician specialty may help target educational and quality improvement initiatives. Using the 1997-2006 National Ambulatory Medical Care Survey, adult ambulatory visits (N=161,278) were classified by cancer diagnosis and patients' characteristics and compared with physician specialty. The prevalence of cancer visits within each specialty varied from 0% to 62%. Aside from hematology/oncology (hem/onc) specialties, nine surgical specialties and four medical specialties had more than 1% cancer visits. Cancer patients with private insurance or Medicaid coverage were less likely to see hem/onc specialists compared to Medicare patients. Whereas hem/onc specialists primarily see cancer patients, general surgeons and primary care physicians provide a large amount of cancer services, particularly to underinsured patients. Thus, when trying to contact cancer patients or their physicians, health administrators, researchers, and practitioners should consider targeting general surgeons and primary care physicians in addition to hem/onc specialists.
volume and better outcomes was previously noted by Luft and colleagues in 1979 [9] . More recent studies further suggest cancer patients receive more appropriate diagnostic and therapeutic interventions or have better outcomes when care is delivered by a specialized hospital or clinician [10, 11] . As compared to generalists, specialists may have higher levels of cancer-specific knowledge and provide more consistent patterns of care by following the most current guidelines for care by cancer type [12] .
Differences in cancer prevention efforts have also been noted across specialties. Feldman demonstrated that skin cancer prevention communication to high-risk patients depends on physician specialty [13] . Bhosle and colleagues showed that breast cancer screening recommendations depend on specialty [14] . Moreover, differences between physician specialties in the practice of preventive medicine have been demonstrated outside the USA [15, 16] .
Although a multitude of personal and institutional factors likely impact access to specialty care, given its more expensive nature, financial considerations and type of insurance are likely part of the complex equation [17, 18] . Patients may either be unaware of the availability of specialist care for their diagnosis or may be in a system such as managed care where choice and referral to specialty are not within their authority [19, 20] . Thus, during an assessment of practice patterns in relation to cancer care, researchers must consider that patient access to specialty services and knowledge of the availability of such services may be limited.
The purpose of this paper is to remind policy makers, clinicians, and researchers to look beyond hematology/ oncology (hem/onc) specialties when trying to contact cancer patients and/or physicians providing care to cancer patients. In order to begin to better understand who sees cancer patients, we examined the prevalence of visits with a primary diagnosis of cancer by physician specialty and compared patient characteristics across specialty. Specifically, using clinical response data from the 1997-2006 National Ambulatory Medical Care Survey (NAMCS), we identified patients who have a primary diagnosis of cancer in an effort to understand which physician specialties delivered a substantive proportion of cancer visits (i.e., greater than 1%). Next, we compared the demographics, health, and expected source of payment of cancer patients by specialty in an effort to determine if patients seen by hem/onc specialists had similar characteristics as patients seen by non-hem/onc specialists.
Methods

National Ambulatory Medical Care Survey
NAMCS is a national survey, developed in 1973, and directed by the US Bureau of the Census to collect information on ambulatory medical care services in the USA [21] . It consists of probability samples of patient visits to practices located within specific geographic areas in the USA and the District of Columbia. Through a complex, multistage sampling process, data are collected via chart reviews from a systematic random sample of patient visits to non-hospital-based physician practices. Response rates are high, but vary by strata (i.e., physician specialty). In 2002, the average response rate was 70.4 and ranged by strata from 57.2 (internal medicine) to 75.5 (general and family practice). Anesthesiologists, pathologists, and radiologists are not surveyed.
Study Sample
From the 254,716 patient visit records in the 1997-2006 NAMCS data, 76,998 were removed, because either the patient was aged 17 or younger or the patient was seen by a pediatrician or pediatric specialist. Among the remaining records, 5,218 were removed, because the patient did not see a physician during his/her visit. An additional 11,165 records describing psychiatric services were removed, because the purpose of this study focuses on the medical and surgical treatment of cancer. Lastly, 57 records were removed due to unknown physician specialty. The resulting sample contained 161,278 records on ambulatory care visits of US adult patients over a 10-year period. A subsample of only records containing patients with a principle diagnosis of malignant neoplasm was created (N=5,122) and served as the basis for the analyses presented in this manuscript. In order to study the utilization of services, the patient visit is analyzed, as opposed to the individual patient.
Measurement
Each individual physician or a designated representative from his or her practice is responsible for performing the random sampling of patient visits and completing NAMCS surveys for data submission. The patient record instrument includes items on patients' symptoms, diagnoses, planned or provided services, and medications prescribed or provided during an office visit. In addition, patients' demographic information and expected source of payment are recorded.
The principal diagnosis for each visit in this study was recorded using the ninth edition three-digit version of the International Statistical Classification of Diseases and Related Health Problems (ICD-9) codes. To measure cancer diagnosis, an indicator variable for neoplasms (ICD-9: 140 to 239) was created. Non-melanoma skin cancer (ICD-9: 173), benign neoplasms (ICD-9: 210 to 229), carcinoma in situ (ICD-9: 230 to 243), and neoplasms of uncertain behavior (ICD-9: 235 to 239) were excluded. Each cancer diagnosis was then categorized by site using the following ICD-9 codes: 140-149 (lip, oral cavity, and pharynx), 150-159 (digestive organs and peritoneum), 160-165 (respiratory and intrathoracic organs), 172 (skin), 174 (breast), 179-189 (genitourinary organs), and 200-208 (lymphatic and hematopoietic tissue). The remaining codes were combined into a summary category (other site).
NAMCS race response was recoded into three indicator variables: White; Black; or other racial minority, a category combining Asian (N=117), American Indian/Alaskan Native/Native Hawaiian/Other Pacific Islander (N=12), and other (N=2). Potential responses for the expected source of payment included private insurance, Medicare, Medicaid, worker's compensation, self-pay, no charge, other, and unknown. Among the cancer cases, self-pay (N=68), other (N=160), and no charge (N=47) responses were combined to create a noninsurance indicator variable. One case of worker's compensation was counted as private insurance, because this may have been a form of employer-funded insurance. However, respondents with unknown insurance status (N=85) were dropped from the analytical analysis in Tables 1 and 2 .
Physician Specialties NAMCS has 70 distinct physician specialties, excluding pediatric specialties [21] . Although the American Medical Association (AMA) categorizes physician specialties as primary care, surgical specialty, and medical specialty [22] , health services researchers have published alternative categorizations of physician specialties. For example, Feldman and colleagues divided physician specialties into family and general practice, internal medicine, pediatrics, general surgery, dermatology, otolaryngology, and all other physicians [13] ; Richardson and Tangka categorized specialties as primary care, general surgery, dermatology, oncology, urology, and other [23] ; and Shepherd separated hem/onc categories into medical oncology, radiation oncology, surgery, hematology, and pediatric oncology [15] . Pollack and colleagues defined cancer specialists to be gynecologic oncologists, hematologists, hematologists/ oncologists, medical oncologists, musculoskeletal oncologists, radiation oncologists, and surgical oncologists [1] . Instead of categorizing physician specialties into several classes, other researchers examined dichotomies, such as obstetrician/gynecologist versus nonobstetrician/gynecologist, or breast oncologists versus surgeons [14, 16] .
For this study, we separated out the hem/onc specialties and applied the AMA definitions, rendering four categories: (1) hem/onc, (2) primary care, (3) surgical specialty, and (4) medical specialty. The hem/onc categorization includes hem/onc, medical oncology, hematology, musculoskeletal oncology, surgical oncology, and gynecological oncology.
Statistical Analyses
Using a binomial probability test, we first examined which of the non-hem/onc physician specialties had a substantial portion of cancer patient visits (greater than 1%). Second, using a chi-square goodness of fit test, we tested whether the demographic characteristics and expected source of payment of cancer patients per patient visit to different categories of non-hem/onc specialists were significantly different from the demographic characteristics and expected source of payment of cancer patients per visit to hem/onc specialists (e.g., primary care versus hem/onc). Third, we compared the characteristics of cancer patients per visit seen by non-hem/onc specialists to those seen by hem/onc specialists using logistic regression. Patient visits to hem/ onc specialists served as the cases, and patient visits to nonspecialists were the controls in the logistic regression models. In addition, the logistic regression models allowed us to examine all cancer visits collectively and then stratify the data by cancer site.
Database management was conducted in SAS 9.1.3; however, the statistical analysis was conducted using STATA MP 9.0 [24, 25] . The analyses did not apply sampling weights, because NAMCS data did not contain sample weights across the 10-year period of data used in our study.
Results
Aside from the five hem/onc specialties, NAMCS has ten primary care specialties, 21 surgical specialties, and 34 medical specialties. The proportion of cancer visits within each specialty varied from 0% to 62%. The binomial probability test results identified no primary care specialties with >1% prevalence of cancer visits; however, eight of the 21 surgical specialties and four of the 34 medical specialties were identified (see Fig. 1 ). Urology had the highest proportion (16%) of cancer visits, followed by general surgery. We combined abdominal, cardiovascular, colorectal, cardiothoracic, thoracic, and vascular surgery as an "other specialty surgery" category. Each of these specialties had a substantial number of cancer visits, ranging from 2.4% to 15.4%, but had fewer observations (ranging from 4 to 22) than the other three specialty surgeries: urology (N=1,931), otolaryngology (N=162), and plastic surgery (N=37).
Next, we examined the subsample of patients with a primary diagnosis of malignant neoplasm. Eighty-five visits were removed due to an unknown source of payment by the patient. Within the subsample (N=5,037), we separated hem/onc specialties and non-hem/onc specialties. The nonhem/onc specialties were further separated by AMA categories: primary care, surgical specialties, and medical specialties. To better capture potential differences, we split surgical specialties by general surgery, urology, and other.
Descriptively, hem/onc specialists served White, midaged or older, non-Hispanic, female patients ( Table 1 ). The typical source of payment was insurance; hem/onc specialists received an alternative source of payment, such as selfpay, for only 6% of visits. The most common cancer was breast cancer (31%) followed by disorders of lymphatic or hematopoietic tissues (20%). Melanoma and oral cancer were the least common (1% for both sites).
Demographics of cancer patients seen by primary care physicians and hem/onc specialists were similar when compared by patient visit. However, primary care physicians were more likely than hem/onc specialists to be visited by Black cancer patients, patients aged 80 or older, and patients whose primary source of payment was not insurance. Also, primary care physicians had less visits involving breast and blood cancers and more involving genitourinary cancers compared to all other physician specialties.
Compared to hem/onc specialists, general surgeons saw less patients aged 80 and older and more patients below 50 years of age as well as female patients, perhaps due to the high proportion of breast cancers (51%). Cancer visits (7) 35 (12) 50 (7) 248 (13) 24 (8) 19 (6) Other race 46 (3) 3 (1) 21 (3) 38 (2) 15 (5) 6 (2) Ethnicity Hispanic 61 (4) 17 (6) 36 (5) 114 (6) (13) 57 (8) 38 (2) 71 (24) 117 (38) Hem/onc includes hematology/oncology, medical oncology, hematology, musculoskeletal oncology, surgical oncology, and gynecological oncology. Surgical specialty excludes general surgery and urology with general surgeons were more likely to be uninsured; however, visits to hem/onc specialists or general surgeons did not demonstrate racial or ethnic differences between patients.
Not surprisingly, urologists were mostly visited by males (93%) and patients with genitourinary cancers (98%). In comparison to hem/onc specialists, the patient population of a urologist by visits included a greater Fig. 1 Proportion of cancer visits by physician specialty. This figure excludes oncology and hematology specialties that primarily serve cancer patients. Other specialty surgery includes thoracic, cardiothoracic, cardiovascular, vascular, abdominal, and colorectal surgery number of Hispanic patients and nearly twice the number of Black patients; a possible correlation to the higher incidence of prostate cancer in minority communities [26, 27] . Compared to hem/onc specialists, urologists also saw older patients who more often utilized Medicare over private insurance. Cancer visits to the remaining surgical specialties, such as thoracic surgeons, plastic surgeons, and otolaryngologists, were for neoplasms in respiratory and intrathoracic organs (23%), or the lips, oral cavity, and pharynx (22%). The remaining medical specialties (e.g., dermatologists, pulmonologists, and gastroenterologists) saw patients for conditions such as malignant melanoma (23%) or neoplasms of digestive or respiratory organs (23%). In terms of demographic and expected source of payment, patients who saw these less common surgical and medical specialties were similar to patients seen by hem/onc specialists.
Results from the logistic regression models are presented in Table 2 . Across all cancer sites, male visits to a hem/onc specialist were less likely than female visits (odds ratio (OR)=0.28; 95% confidence interval (CI), 0.25, 0.32). Compared to visits by White cancer patients, visits by Black cancer patients were less likely to be to hem/onc specialists (OR=0.68; 95% CI, 0.53, 0.86), as were visits by cancer patients without private insurance (OR=0.69; 95% CI, 0.57, 0.83). Compared to visits by cancer patients aged 65 to 80, visits by those in younger age groups were more likely to be to a cancer specialist (OR=1.48; 95% CI, 1.17, 1.88 and OR=1.47; 95% CI, 1.21, 1.80, respectively).
When examined by cancer site, there were few statistically significant relationships between cancer patient characteristics and the odds of seeing a hem/onc specialist versus seeing a non-hem/onc specialist. The only significant difference among colorectal cancer visits was expected source of payment. Compared to visits by patients with Medicare coverage, visits by colorectal cancer patients with other payment sources (e.g., private pay) were less likely to be received by a hem/onc specialist (OR=0.43; 95% CI, 0.19, 0.96). Among visits by male patients with genitourinary cancer, visits by younger cancer patients (age less than 50) were more likely to be to a hem/onc specialist (OR= 3.02; 95% CI, 1.39, 6.55). Statistically significant age and payment source differences were also noted among female patients with breast cancer. Hem/onc specialists saw more female breast cancer patients below 65 years of age than those aged 65 to 80 (OR=1.75; 95% CI, 1.07, 2.84 and OR=1.61; 95% CI, 1.05, 2.45, respectively). However, compared to visits covered by Medicare, visits by female breast cancer patients with private insurance or other payment sources were less likely to be to hem/onc specialists (OR=0.47; 95% CI, 0.31, 0.72 and OR=0.45; 95% CI, 0.25, 0.82).
Discussion
In this study, we use data from NAMCS to answer the question, "Who sees cancer patients?" Although oncologists and other hem/onc specialists seem to be the obvious answer to this question, our findings suggest otherwise. Within the population of adult patients in the USA, no primary care specialties have >1% prevalence of cancer visits; however, eight of the 21 surgical specialties and four of the 34 medical specialties see a substantive proportion of cancer visits.
In the 2009 study by Pollack and colleagues, non-cancer specialists, such as general surgeons, were excluded, even if they saw a large portion of cancer patients [1] . Their study found a large effect of misclassification in surgical and gynecologic oncology is demonstrated with the use of Medicare claims. In complement to their study, this surveybased study extends the target population of educational interventions to non-cancer specialists (e.g., general surgeons and urologists) based on evidence that these specialists see a large portion of cancer patients.
The characteristics of cancer visits to non-hem/onc specialists versus to hem/onc specialists are substantially different. Primary care physicians and general surgeons have more visits without an insured source of payment than hem/onc specialists. Urologists and primary care physicians saw more Black cancer patients than hem/onc specialists. Visits to urologists are largely by male patients, and visits to hem/onc specialists and general surgeons are mostly by female patients.
Controlling for cancer patient characteristics further identifies statistically significant relationships between physician specialty and patient sex, race, and expected source of payment. Hem/onc specialists saw fewer male cancer patients compared to female cancer patients. This pattern may be attributed to the fact that urologists receive a large proportion of cancer visits (16%) and most are by males (93%). Nevertheless, hem/onc specialists saw fewer male colorectal cancer patients than female colorectal cancer patients, although this result is not statistically significant.
In the USA, the relationship between age and specialty care may be confounded by health insurance. The vast majority of adults (95%) over age 65 qualify for Medicare, but only 4% of adults under age 65 qualify, leaving many cancer patients under age 65 without health insurance [28] [29] [30] . Due to the coincidence of age 65 and insurance, these characteristics must be interpreted together. Based on the results, Medicare increases the likelihood of seeing a hem/ onc specialist, but this effect is lessened among patients aged 80 and older. Compared to adults aged 65 and older, younger cancer patients are more likely to visit a hem/onc specialist, regardless of expected source of payment. The bias favoring specialty care for younger patients may be attributable to age-specific recommendations in the treatment of cancer [31, 32] .
Even after controlling for patient age, gender, ethnicity, and payment source, hem/onc specialists saw fewer Blacks than other physicians. Epidemiologic data suggest Blacks tend to be diagnosed at later stages [33] [34] [35] and, in the case of breast cancer, with more aggressive forms of the disease when compared to Whites [36] . In general, chemotherapeutic interventions are more likely part of the standard treatment protocol for later stage cancers than those diagnosed at earlier stages. Thus, this finding is particularly surprising. These results may provide some insight into the overall disparities in patient survival observed between Blacks and Whites by cancer site. Since non-hem/onc specialists see a disproportionate share of affected communities, efforts to reduce cancer care disparities through educational initiatives may find it necessary to target a broad based group of specialists, including non-hem/onc specialists and their patients.
This study is among the first reports of physician specialties and the differences between cancer patients who visit hem/onc specialists and non-hem/onc specialists over a 10-year period. However, several limitations should be considered when interpreting the findings of this study. First, the analysis did not account for NAMCS sampling protocol. Sample weights applicable to the nature of our statistical analyses were not provided; thus, certain populations may be broadly underrepresented or overrepresented. Likewise, standard errors may similarly be downward biased due to clustering at the clinic level. Second, although the sample size is relatively large (N=5,037), minority populations compose a small proportion of the sample. This is particularly important in the logistic regressions models used to examine patient attributes by cancer site, which may have power less than 0.80 to identify racial and ethnic disparities. Third, we classified cancer visits based on the primary ICD-9 code that identifies cancer and labeled it diagnostic. Reliance on ICD-9 codes to characterize patient care may not distinguish between the receipt of cancer care and unrelated care. Fourth, an arbitrary prevalence cutoff (1%) was applied to emphasize the prevalence of cancer visits among certain specialties. We conducted a sensitivity analysis varying this cutoff from 0.1% to 5%, which did not meaningfully change the results.
The findings in this paper support the notion that research and educational initiatives aimed at cancer patients and/or physicians treating cancer patients should target hem/onc and other specialists alike. Doing so may improve the capacity of clinical, policy, and educational interventions that promote the quality of cancer care delivery and reach a diversity of cancer patient populations. For instance, studies examining patient outcomes by hem/onc versus other specialties have found differences related to quality. McClave, Jones, and Evans found that internists and primary care physicians are less likely compared to all other physician specialties to order the recommended tests for esophageal cancer as identified by national guidelines [37] . They suggest that disease staging and treatment may be impacted by the nonuse of recommended tests. Thus, health services research and educational interventions in the area of esophageal cancer indicate a need to include the full range of physician specialties that see cancer patients to increase awareness of and adherence to the most current standardized cancer care guidelines.
Future research may include the evaluation of specialties in surveillance of and quality initiatives in cancer. Perez makes a similar call for the identification and inclusion of all relevant physician types to improve the quality of care for non-small cell lung cancer [38] . This review reveals that different physician specialties and subspecialties have equally different opinions on disease management; it suggests that as new treatment guidelines and therapies are developed, dissemination of knowledge should be directed at audiences beyond the traditional medical oncologist. Mandelblatt et al. [39] found differences in the treatment and follow-up recommendations for early stage breast cancer, such as non-oncology specialists ordering tests and follow-up outside recommended guidelines. Therefore, further research is needed to identify the prevalence of inconsistencies in the quality of cancer care in relation to physician type. This evidence suggests that current research trends, which focus on the opinions of oncologists in the care of cancer patients, may not represent the full spectrum of providers who treat cancer patients.
